{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T21:45:41Z","timestamp":1740174341912,"version":"3.37.3"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,2,19]],"date-time":"2016-02-19T00:00:00Z","timestamp":1455840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004330","name":"Glaxosmithkline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1007\/s40801-015-0057-y","type":"journal-article","created":{"date-parts":[[2016,2,19]],"date-time":"2016-02-19T10:40:04Z","timestamp":1455878404000},"page":"53-60","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Intranasal Fluticasone Propionate Observational Cohort Safety Studies: Reviewing Evidence from Databases on Two Continents"],"prefix":"10.1007","volume":"3","author":[{"given":"Kourtney J.","family":"Davis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Hinds","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen P.","family":"Motsko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"Earl","family":"Goehring","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith K.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,2,19]]},"reference":[{"issue":"Suppl 86","key":"57_CR1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.1398-9995.2007.01620.x","volume":"63","author":"J Bousquet","year":"2008","unstructured":"Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, GA(2)LEN, AllerGen, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63(Suppl 86):8\u2013160. doi: 10.1111\/j.1398-9995.2007.01620.x .","journal-title":"Allergy"},{"issue":"1","key":"57_CR2","first-page":"1","volume":"22","author":"J Sastre","year":"2012","unstructured":"Sastre J, Mosges R. Local and systemic safety of intranasal corticosteroids. J Investig Allergol Clin Immunol. 2012;22(1):1\u201312.","journal-title":"J Investig Allergol Clin Immunol"},{"key":"57_CR3","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.amjoto.2007.11.004","volume":"29","author":"P Demoly","year":"2008","unstructured":"Demoly P. Safety of intranasal corticosteroids in acute rhinosinusitis. Am J Otolaryngol. 2008;29:403\u201313. doi: 10.1016\/j.amjoto.2007.11.004 .","journal-title":"Am J Otolaryngol"},{"key":"57_CR4","doi-asserted-by":"publisher","first-page":"317","DOI":"10.2165\/00002018-200730040-00004","volume":"30","author":"M Zitt","year":"2007","unstructured":"Zitt M, Kosoglou T, Hubbell J. Mometasone furoate nasal spray: a review of safety and systemic effects. Drug Saf. 2007;30:317\u201326.","journal-title":"Drug Saf"},{"key":"57_CR5","unstructured":"Global Initiative for Asthma. The global strategy for asthma management and prevention (updated 2012). http:\/\/www.ginasthma.org . Accessed 29 June 2014."},{"key":"57_CR6","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1542\/peds.92.4.594","volume":"92","author":"J Grossman","year":"1993","unstructured":"Grossman J, Banov C, Bronsky EA, Nathan RA, Pearlman D, Winder JA, Ratner PH, Mendelson L, Findlay SR, Kral KM, Field EA, Rogenes PR. Fluticasone propionate aqueous nasal spray is safe and effective for children with seasonal allergic rhinitis. Pediatrics. 1993;92:594\u20139.","journal-title":"Pediatrics"},{"key":"57_CR7","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/S0022-3476(94)70025-7","volume":"125","author":"Fluticasone Propionate Collaborative Pediatric Working Group","year":"1994","unstructured":"Fluticasone Propionate Collaborative Pediatric Working Group. Treatment of seasonal allergic rhinitis with once daily intranasal fluticasone propionate therapy in children. J Pediatr. 1994;125:628\u201334.","journal-title":"J Pediatr"},{"key":"57_CR8","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1542\/peds.112.1.96","volume":"112","author":"SP Galant","year":"2003","unstructured":"Galant SP, Melamed IR, Nayak AS, Blake KV, Prillaman BA, Reed KD, Cook CK, Philpot EE, Rickard KA. Lack of effect of fluticasone propionate aqueous nasal spray on the hypothalamic-pituitary-adrenal axis in 2- and 3-year-old patients. Pediatrics. 2003;112:96\u2013100.","journal-title":"Pediatrics"},{"key":"57_CR9","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S0091-6749(98)70085-5","volume":"102","author":"R Vargas","year":"1998","unstructured":"Vargas R, Dockhorn RJ, Findlay SR, Korenblat PE, Field EA, Kral KM. Effect of fluticasone propionate aqueous nasal spray versus oral prednisone on the hypothalamic-pituitary-adrenal axis. J Allergy Clin Immunol. 1998;102:191\u20137.","journal-title":"J Allergy Clin Immunol."},{"key":"57_CR10","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/S1081-1206(10)63235-8","volume":"78","author":"J Ngamphaiboon","year":"1997","unstructured":"Ngamphaiboon J, Thepchatri A, Chatchatee P, Chumdermpadetsuk S. Fluticasone propionate aqueous nasal spray treatment for perennial allergic rhinitis in children. Ann Allergy Asthma Immunol. 1997;78:479\u201384.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"57_CR11","first-page":"407","volume":"23","author":"DB Allen","year":"2002","unstructured":"Allen DB, Meltzer EO, Lemanske RF Jr, Philpot EE, Faris MA, Kral KM, Prillaman BA, Rickard KA. No growth suppression in children treated with the maximum recommended dose of fluticasone propionate aqueous nasal spray for one year. Allergy Asthma Proc. 2002;23:407\u201313.","journal-title":"Allergy Asthma Proc."},{"issue":"Suppl 3","key":"57_CR12","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/j.1365-2222.1996.tb00654.x","volume":"26","author":"WC Howland 3rd","year":"1996","unstructured":"Howland WC 3rd. Fluticasone propionate: topical or systemic effects? Clin Exp Allergy. 1996;26(Suppl 3):18\u201322.","journal-title":"Clin Exp Allergy"},{"key":"57_CR13","doi-asserted-by":"crossref","unstructured":"Garcia Rodriguez LA, Perez-Gutthann S, Jick S. The UK general practice research database. In: Strom BL, editor. Pharmacoepidemiology. John Wiley & Sons Ltd: West Sussex, England; 2000. p. 375\u201385.","DOI":"10.1002\/0470842555.ch23"},{"issue":"9084","key":"57_CR14","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/S0140-6736(97)04248-7","volume":"350","author":"T Walley","year":"1997","unstructured":"Walley T, Mantgani A. The UK general practice research database. Lancet. 1997;350(9084):1097\u20139.","journal-title":"Lancet"},{"key":"57_CR15","doi-asserted-by":"publisher","DOI":"10.1111\/all.12235","author":"G Roberts","year":"2013","unstructured":"Roberts G, Xatzipsalti M, Borrego LM, Custovic A, Halken S, Hellings PW, Papadopoulos NG, Rotiroti G, Scadding G, Timmermans F, Valovirta E. Paediatric rhinitis: position paper of the European Academy of Allergy and Clinical Immunology. Allergy. 2013;. doi: 10.1111\/all.12235 .","journal-title":"Allergy"},{"issue":"6","key":"57_CR16","doi-asserted-by":"publisher","first-page":"413","DOI":"10.2500\/aap.2011.32.3473","volume":"32","author":"MS Blaiss","year":"2011","unstructured":"Blaiss MS. Safety update regarding intranasal corticosteroids for the treatment of allergic rhinitis. Allergy Asthma Proc. 2011;32(6):413\u20138. doi: 10.2500\/aap.2011.32.3473 .","journal-title":"Allergy Asthma Proc."}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-015-0057-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40801-015-0057-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-015-0057-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-015-0057-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,4]],"date-time":"2022-06-04T15:48:31Z","timestamp":1654357711000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40801-015-0057-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,19]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["57"],"URL":"https:\/\/doi.org\/10.1007\/s40801-015-0057-y","relation":{},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"type":"print","value":"2199-1154"},{"type":"electronic","value":"2198-9788"}],"subject":[],"published":{"date-parts":[[2016,2,19]]},"assertion":[{"value":"19 February 2016","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The analyses were conducted in de-identified electronic medical record\/insurance claims databases. The manuscript does not contain clinical studies or patient data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}},{"value":"KJD and DH are full-time employees of GlaxoSmithKline (GSK) R&D; KJD is a GSK shareholder. These studies were funded by GSK. The decision to submit for publication is in accordance with GSK\u2019s data disclosure and dissemination policy for transparent conduct of research activities. The authors had full control of all primary data and agree to allow the journal to review their data if requested. Stephen Motsko was formerly employed by The Degge Group, Ltd., and is currently employed by Eli Lilly.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study reports and results of the two studies summarized appear on the GSK Clinical Study Register ().","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Prior postings and presentations"}}]}}